Your email has been successfully added to our mailing list.

×
0.00095524017467259 0.00081877729257645 0.00136462882096082 0.000545851528384365 0.00109170305676854 -0.00341157205240175 -0.00300218340611352 -0.0058679039301309
Stock impact report

European advisory group backs ViiV's cabotegravir and rilpivirine regimen in HIV [Seeking Alpha]

GlaxoSmithKline Plc (GSK)  More Company Research Source: Seeking Alpha
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF The European Medicines Agency's advisory group CHMP hasadopted a positive opinionViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline(NYSE:GSKPFEOTCPK:SGIOF [Read more]
Impact snapshot Event time: GSK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
GSK alerts
from News Quantified
Opt-in for
GSK alerts

from News Quantified
Opt-in for
GSK alerts

from News Quantified